PRESS RELEASES Amir Reichman 8/1/23 Amir Reichman 8/1/23 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Read More Amir Reichman 6/5/23 Amir Reichman 6/5/23 BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Read More Amir Reichman 5/15/23 Amir Reichman 5/15/23 BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update Read More Amir Reichman 4/17/23 Amir Reichman 4/17/23 BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update Read More Amir Reichman 3/16/23 Amir Reichman 3/16/23 BiondVax to Present at BIO-Europe Spring Read More Amir Reichman 2/2/23 Amir Reichman 2/2/23 BiondVax Presenting at BIO CEO & Investor Conference Read More Amir Reichman 1/23/23 Amir Reichman 1/23/23 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study Read More Amir Reichman 1/6/23 Amir Reichman 1/6/23 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Read More Amir Reichman 1/5/23 Amir Reichman 1/5/23 BiondVax to Present at Biotech Showcase 2023 Read More Newer Posts
Amir Reichman 8/1/23 Amir Reichman 8/1/23 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Read More
Amir Reichman 6/5/23 Amir Reichman 6/5/23 BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Read More
Amir Reichman 5/15/23 Amir Reichman 5/15/23 BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update Read More
Amir Reichman 4/17/23 Amir Reichman 4/17/23 BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update Read More
Amir Reichman 2/2/23 Amir Reichman 2/2/23 BiondVax Presenting at BIO CEO & Investor Conference Read More
Amir Reichman 1/23/23 Amir Reichman 1/23/23 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study Read More
Amir Reichman 1/6/23 Amir Reichman 1/6/23 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Read More
